GKOS vs SSII
GKOS: A commercial-stage ophthalmic medical technology and pharmaceutical company focused on novel, dropless therapies for glaucoma, corneal disorders, and retinal diseases. SSII: SS Innovations International is a medical technology company specializing in the development and manufacture of robotic-assisted surgical systems.
Side-by-side fundamentals
| Metric | GKOS | SSII | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $166.72 | $3.96 | |
| Market cap as of 2026-08-03 | $9.8B | $797M | |
| PEG as of 2026-08-03 | -0.53 | n/a | |
| Net margin as of 2026-08-03 | -34.3% | -20.7% | SSII higher |
| Gross margin as of 2026-08-03 | +78.1% | +49.1% | GKOS higher |
| Operating margin as of 2026-08-03 | -36.0% | -12.6% | SSII higher |
| ROE as of 2026-08-03 | -26.5% | -23.0% | SSII higher |
| ROA as of 2026-08-03 | -20.1% | -13.2% | SSII higher |
| Debt / equity as of 2026-08-03 | 0.10 | 0.20 | GKOS lower |
| Revenue growth (YoY) as of 2026-08-03 | +36.3% | +42.6% | SSII higher |
| Revenue CAGR (3y) SEC XBRL | +21.5% | +209.3% | SSII higher |
| Beta as of 2026-08-03 | 1.27 | -78.02 | |
| 1-year return as of 2026-07-31 close | +93.7% | -44.8% | GKOS higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.